IL6 and COVID-19: In a previous study by Manganotti et al. [31], elevated levels of interleukins IL-6 and IL-8 were observed in both cerebrospinal fluid and serum during the acute phase of COVID-19 neuropathy in patients with Guillain-Barré syndrome [31].